These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28850025)

  • 1. Improved adalimumab dose decision with comprehensive diagnostics data.
    Zänker M; Becher G; Arbach O; Maurer M; Stuhlmüller B; Schäfer A; Strohner P; Brand J
    Clin Exp Rheumatol; 2018; 36(1):136-139. PubMed ID: 28850025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis.
    L' Ami MJ; Ruwaard J; Krieckaert C; Nurmohamed MT; van Vollenhoven RF; Rispens T; Wolbink GJ
    Scand J Rheumatol; 2019 Jul; 48(4):266-270. PubMed ID: 31012365
    [No Abstract]   [Full Text] [Related]  

  • 3. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
    Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL
    Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
    Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
    Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug outcome survey to evaluate anti-TNF treatment in rheumatoid arthritis: an Italian observational study (the DOSE study).
    Anecchino C; Fanizza C; Marino V; Romero M;
    Clin Exp Rheumatol; 2015; 33(6):779-87. PubMed ID: 26575614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.
    Cuchacovich M; Catalan D; Wainstein E; Gatica H; Soto L; Aravena O; Pesce B; Sabugo F; Aguillón JC
    Clin Exp Rheumatol; 2008; 26(6):1067-73. PubMed ID: 19210871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
    Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Percentage of Signal Regulatory Protein α/β
    Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C
    Front Immunol; 2018; 9():2865. PubMed ID: 30568660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe.
    Holden SE; Currie CJ; Lennon M; Reynolds AV; Moots RJ
    Clin Exp Rheumatol; 2016; 34(4):679-84. PubMed ID: 27191345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice.
    Huang X; Gu NY; Fox KM; Harrison DJ; Globe D
    Curr Med Res Opin; 2010 Jul; 26(7):1637-45. PubMed ID: 20429830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice.
    Rosas J; Llinares-Tello F; de la Torre I; Santos-Ramírez C; Senabre-Gallego JM; Valor L; Barber-Vallés X; Hernández-Flórez D; Santos-Soler G; Salas-Heredia E; Carreño L;
    Clin Exp Rheumatol; 2014; 32(6):942-8. PubMed ID: 25327159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
    Moots RJ; Haraoui B; Matucci-Cerinic M; van Riel PL; Kekow J; Schaeverbeke T; Davis A; Tedeschi MA; Freundlich B; Chang DJ; Singh A
    Clin Exp Rheumatol; 2011; 29(1):26-34. PubMed ID: 21345289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study).
    Fautrel B; Pham T; Alfaiate T; Gandjbakhch F; Foltz V; Morel J; Dernis E; Gaudin P; Brocq O; Solau-Gervais E; Berthelot JM; Balblanc JC; Mariette X; Tubach F
    Ann Rheum Dis; 2016 Jan; 75(1):59-67. PubMed ID: 26103979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.
    Berkhout LC; Vogelzang EH; Hart MM; Loeff FC; Dijk L; Derksen NIL; Wieringa R; van Leeuwen WA; Krieckaert CLM; de Vries A; Nurmohamed MT; Wolbink GJ; Rispens T
    Clin Exp Rheumatol; 2020; 38(2):306-313. PubMed ID: 31498069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.